drugset / Trial / NCT02079922

A Multiple Dose Study Of PF-06678552 In Healthy Subjects

NCT02079922 ↗

Phase 1 Completed 38 enrolled Pfizer
RandomizedParallel-groupTriple-blindBasic science

Summary

PF-06678552 is a new compound proposed for the treatment of hypercholesteremia. The primary purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of PF-06678552 in healthy subjects.

Timeline

Start
2014-03
Primary completion
2014-07
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-06678552 Unknown — —

Indications

No indication recorded.